Avelumab plus axitinib vs sunitinib in patients (pts) with advanced renal cell carcinoma (aRCC): Final overall survival (OS) analysis from the JAVELIN Renal 101 phase 3 trial Meeting Abstract
| Authors: | Motzer, R. J.; Penkov, K.; Uemura, H.; Campbell, M. T.; Kollmannsberger, C. K.; Lee, J. L.; Venugopal, B.; Van Den Eertwegh, A.; Negrier, S.; Gurney, H.; Albiges, L.; Berger, R.; Haanen, J.; Rini, B. I.; Larkin, J.; Schmidinger, M.; Sandner, R.; Wang, J.; Di Pietro, A.; Choueiri, T. K. |
| Abstract Title: | Avelumab plus axitinib vs sunitinib in patients (pts) with advanced renal cell carcinoma (aRCC): Final overall survival (OS) analysis from the JAVELIN Renal 101 phase 3 trial |
| Meeting Title: | 2024 ASCO Annual Meeting |
| Journal Title: | Journal of Clinical Oncology |
| Volume: | 42 |
| Issue: | 16 Suppl. |
| Meeting Dates: | 2024 May 31-Jun 4 |
| Meeting Location: | Chicago, IL |
| ISSN: | 0732-183X |
| Publisher: | American Society of Clinical Oncology |
| Date Published: | 2024-06-01 |
| Language: | English |
| ACCESSION: | WOS:001275557401155 |
| PROVIDER: | wos |
| DOI: | 10.1200/JCO.2024.42.16_suppl.4508 |
| Notes: | Meeting Abstract: 4508 -- Source: Wos |
